From Multivalency to Biomarker-Guided Delivery: Integrating Breakthroughs for the Future of Targeted Protein Degradation

Recent advances in targeted protein degradation combine dual E3 ligase-recruiting multivalent PROTACs, Survivin as a predictive biomarker for therapeutic responsiveness, and dendrimer-PROTAC conjugates for CNS and inflammation-targeted delivery. Together, these innovations form a synergistic framework for potent, selective, and biomarker-guided degraders with enhanced delivery, offering a promising blueprint for next-generation therapeutics in oncology and beyond.